.
.
.
Large Molecule Bioanalysis
Precision Quantification of Proteins, Peptides & Antibodies
At ResolveMass Laboratories Inc., our expertise in Large Molecule Bioanalysis empowers scientists and biopharma innovators to accurately quantify proteins, peptides, and antibodies through advanced LC-MS/MS and hybrid analytical platforms. We deliver reliable, GLP-compliant results that accelerate drug discovery and biologics development.
Introduction
At ResolveMass Laboratories Inc., we specialize in Large Molecule Bioanalysis—a critical field that underpins the development and validation of biologics including proteins, peptides, and antibodies. Our state-of-the-art LC-MS/MS and ligand-binding technologies enable precise quantification and characterization of therapeutic molecules, ensuring regulatory compliance and scientific integrity.
With deep experience in bioanalytical method development, our scientists provide end-to-end solutions that help biotech and pharmaceutical innovators accelerate their discovery-to-clinic timelines.
Explore our Bioanalytical Quantification Services →
Expertise
Proteins
ResolveMass delivers advanced protein bioanalysis using LC-MS/MS and hybrid LBA-MS approaches. From quantifying therapeutic proteins to detecting trace-level impurities, our validated assays ensure confidence in your biopharmaceutical data.
Peptides
Our peptide bioanalysis methods are optimized for complex biological matrices. We develop and validate custom assays with superior accuracy, reproducibility, and sensitivity — supporting preclinical and clinical phases alike.
Antibodies
We specialize in antibody bioanalysis, including monoclonal and bispecific antibodies. Our platform integrates targeted proteomics and immunocapture techniques to provide highly specific and quantitative insights.
Learn More: Biomarker Quantification at ResolveMass →
Why Choose ResolveMass?
- Scientific Expertise: A team of PhD-level scientists specializing in LC-MS and bioanalytical assay design.
- Regulatory Compliance: Fully GLP-compliant workflows aligned with FDA, EMA, and Health Canada guidelines.
- Custom Solutions: Tailored method development for novel modalities and complex biologics.
- Proven Results: Successful track record with global pharma and biotech clients.
- Advanced Infrastructure: State-of-the-art mass spectrometry and ligand-binding platforms.
Read: How to Select the Best CRO for LC-MS Bioanalysis →
Our Bioanalytical Workflow
Consultation & Study Design – Collaborative planning with your R&D team.
Method Development – Custom assay creation for protein, peptide, or antibody targets.
Validation – Comprehensive regulatory validation following GLP standards.
Sample Analysis – High-throughput and high-sensitivity quantification.
Data Interpretation & Reporting – Accurate, reproducible, and audit-ready results.
Conclusion
In conclusion, Large Molecule Bioanalysis at ResolveMass Laboratories Inc. combines scientific precision, regulatory alignment, and deep expertise in proteins, peptides, and antibodies. Our proven methodologies and collaborative approach empower biotech innovators to move from discovery to market with confidence.
Explore All Bioanalytical Solutions →
Contact ResolveMass Today
Frequently Asked Questions
Large Molecule Bioanalysis refers to the quantification and characterization of complex biological therapeutics such as proteins, peptides, and antibodies. It involves analytical techniques like LC-MS/MS and ligand-binding assays to ensure accuracy and regulatory compliance.
It ensures therapeutic molecules are accurately measured in biological samples, validating their safety, efficacy, and pharmacokinetic properties during clinical trials.
We use hybrid LBA-MS and LC-MS/MS platforms to measure proteins with high sensitivity and specificity, ensuring reliable quantification even in complex matrices.
Our peptide bioanalysis integrates chromatographic separation, tandem mass spectrometry, and stable isotope-labeled standards for precise quantification.
Antibodies are structurally complex and require highly specific methods to distinguish between therapeutic antibodies and endogenous immunoglobulins. ResolveMass overcomes these challenges using immunocapture LC-MS and validated ligand-binding assays.
Yes, all methods are developed and validated under GLP standards to meet regulatory requirements from the FDA, EMA, and Health Canada.
Absolutely. Our scientists collaborate with your R&D team to design assays tailored to your molecule’s structure, stability, and matrix environment.
References
- Stevenson, L., Kelley, M., Gorovits, B., Kingsley, C., Myler, H., Österlund, K., Muruganandam, A., Minamide, Y., & Dominguez, M. (2014). Large molecule specific assay operation: Recommendation for best practices and harmonization from the Global Bioanalysis Consortium Harmonization Team. The AAPS Journal, 16(1), 83-88. https://doi.org/10.1208/s12248-013-9542-y
- Wuxi AppTec. (2024, September 12). Small vs. Large Molecule Bioanalysis: 7 key differences. https://labtesting.wuxiapptec.com/2024/09/12/small-vs-large-molecule-bioanalysis-7-key-differences/
- Thway, T. M. (2016). Fundamentals of large-molecule protein therapeutic bioanalysis using ligand-binding assays. Bioanalysis, 8 (1), 11-17. https://doi.org/10.4155/bio.15.199